重庆医学Issue(16)：2228-2230,3.DOI:10.3969/j.issn.1671-8348.2015.16.024
艾塞那肽对2型糖尿病合并非酒精性脂肪性肝病的肝脏病变治疗评估
The effective assessment of diabetes mellitus and nonalcoholic fatty liver disease treated by Exenatide
蒲永莉 1李彦 2罗春梅 3王雪 1谢家鑫1
作者信息
- 1. 重庆三峡医药高等专科学校临床医学系 400412
- 2. 重庆三峡中心医院内分泌科 400412
- 3. 重庆市中医院药剂科 400021
- 折叠
摘要
Abstract
Objective To assess the effectiveness of Exenatide on non‐alcoholic fatty liver disease(NAFLD) with diabetes mellitus by evaluating fatty liver index(FLI) variation .Methods One hundred and two NAFLD patients with type 2 diabetes melli‐tus were enrolled and divided into two groups .One group were treated with Exenatide and another with Oral antidiabetic agents . The data of BMI ,blood fat ,HbA1c ,ALT ,AST ,GGT ,FLI and so on were collected at enrollment and the end point of 24 weeks treatment .The effectiveness of Exenatide were analysed by Kolmogorov‐Smirnov and Pearson correlation coefficient (r) analysis . Results The indicators of metabolic disorder ,the parameters of liver biochemistry and fatty liver disease (FLI) were significantly improved (P<0 .05) after 24 weeks treatment by Exenatide .While only BMI showed significant decrease after 24 weeks treatment with Oral antidiabetic agents(P<0 .05) .The rest of the parameters in oral antidiabetic agants group showed no significant differ‐ence (P>0 .05) .Conclusion Exenatide has a positive effect on non‐alcoholic fatty liver disease treatment who with type 2 diabetes mellitus ,especially for liver fat accumulation .关键词
艾塞那肽/糖尿病 ,2型/脂肪肝/脂肪肝指数Key words
Exenatide/diabetes ,type 2/one hundred and one fatty liver分类
医药卫生引用本文复制引用
蒲永莉,李彦,罗春梅,王雪,谢家鑫..艾塞那肽对2型糖尿病合并非酒精性脂肪性肝病的肝脏病变治疗评估[J].重庆医学,2015,(16):2228-2230,3.
